Trademark Search in Canada

Relatlimab Logo

View On IC.GC.CA

REGISTERED

on 27 Dec 2024

Last Applicant/ Owned by

Bristol-Myers Squibb Company

Route 206 & Province Line RoadPrinceton, NJ 08543

Serial Number

2046633 filed on 20^th Aug 2020

Registration Number

TMA1278335 registered on 27^th Dec 2024

Registration expiry Date

27^th Dec 2034

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

M5X1G5

Relatlimab Logo

Trademark usage description

pharmaceutical preparations for human use for the treatment of cancer health care services, namely, providing information to physicians, health care Read More

Vienna Information

26 . 2 . 1

Segments of circles or ellipses (except 26.2.7)Segments de cercle ou d'ellipse (excepté 26.2.7)

26 . 11 . 1

One line or one bandUne ligne ou une bande

26 . 11 . 2

Two lines or bandsDeux lignes ou bandes

26 . 11 . 6

Thick lines, bandsLignes épaisses, bandes

26 . 11 . 11

Broken lines or bands (except a 26.11.13)Lignes ou bandes brisées (excepté a 26.11.13)

26 . 11 . 12

Curved lines or bands (except a 26.11.13)Lignes ou bandes courbes (excepté a 26.11.13)

Classification Information

Class [005]
Pharmaceutical preparations for human use for the treatment of cancer

Classification kind code

Class [044]
Health care services, namely, providing information to physicians, health care professionals and patients on the topic of health issues, health awareness and pharmaceuticals in the field of cancer; Providing medical information in the field of cancer patient healthcare and pharmaceutical preparations for the treatment of cancer, via a website;

Classification kind code

Mark Details

Serial Number

2046633

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 42 on 9^th Oct 2024	Advertised
Submitted for opposition 26 on 10^th Sept 2024	Approved
Submitted for opposition 27 on 10^th Sept 2024	Approval Notice Sent
Submitted for opposition 22 on 6^th Aug 2024	Search Recorded
Submitted for opposition 20 on 6^th Aug 2024	Examiner's First Report
Submitted for opposition 135 on 6^th Sept 2023	Amendment to Application
Submitted for opposition 287 on 20^th Jun 2022	Pre-Assessment Letter Sent
Submitted for opposition 30 on 20^th Aug 2020	Filed
Submitted for opposition 1 on 20^th Aug 2020	Created
Submitted for opposition 31 on 20^th Aug 2020	Formalized

Relatlimab Logo

Classification Information

Class [005]Pharmaceutical preparations for human use for the treatment of cancer

Classification kind code

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [005]
Pharmaceutical preparations for human use for the treatment of cancer